However, a retrospective study performed in diverse tumor types showed that patients treated with bevacizumab (an anti-angiogenic antibody targeting VEGF-A) and harboring mutant TP53 had significantly longer progression-free survival than those with wild-type TP53 (p<0.001)[6]. This evidence concerns the gene TP53 and neoplasm.